Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $49.61M at the end of Q1 FY2026, down 0.4% from a year earlier and down 36.0% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.
Context
- Cash & equivalents amounted to 17.4% of total assets at the end of Q1 FY2026, up 6.8 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -0.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 77.56M USD
- Year-over-year change
- -52.6%
- 4-year CAGR
- -24.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.56M | -52.6% |
| FY2024 | 2024-12-31 | 163.64M | +192.7% |
| FY2023 | 2023-12-31 | 55.9M | -60.2% |
| FY2022 | 2022-12-31 | 140.52M | -39.6% |
| FY2021 | 2021-12-31 | 232.69M | — |
Cash & Equivalents vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's Mar 2026 cash & equivalents of $49.61M is the 7th highest of the 10 companies compared; the peer median is $130.93M.
- Its year-over-year change of -0.4% is the 8th highest of 10, against a peer median of +80.4%.
- Cash & equivalents amounts to 17.4% of total assets for RCKT, versus a peer median of 66.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $297.74M | +41.4% | -27.2% | 70.4% | |
| Mar 2026 | $229.2M | +1668.2% | -2.5% | 86.0% | |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $130.93M | +36.7% | -35.2% | 24.8% | |
| Mar 2026 | $84.79M | +121.8% | -21.2% | 61.6% | |
| Mar 2026 | $49.61M | -0.4% | -18.0% | 17.4% | |
| Mar 2026 | $36.2M | -2.9% | -36.5% | 17.0% | |
| Mar 2026 | $14.11M | +89.9% | -1.6% | 89.5% | |
| Mar 2026 | $12.77M | -6.6% | -14.0% | 5.5% | |
| Peer median (excluding RCKT) | $130.93M | +80.4% | -14.0% | 66.6% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 232.69M | 140.52M | 55.9M | 163.64M | 77.56M |
| Short-term Investments | 156.05M | 215.88M | 317.27M | 208.7M | 111.37M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.67M | 5.05M | 5.85M | 3.81M |
| Total Current Assets | 392.06M | 364.06M | 378.22M | 378.18M | 192.73M |
| Property, Plant & Equipment (Net) | 72.35M | 77.65M | 87.59M | 83.32M | 71.59M |
| Goodwill | 30.82M | 39.15M | 39.15M | 39.15M | 39.15M |
| Intangible Assets | 0 | 25.72M | 25.15M | 25.15M | 25.15M |
| Long-term Investments | 0 | 43.28M | 34.32M | 0 | 1.34M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.8M | 1.95M | 1.91M | 1.89M | 482K |
| Total Non-current Assets | 104.96M | 187.75M | 188.12M | 149.52M | 137.72M |
| Total Assets | 497.02M | 551.81M | 566.34M | 527.7M | 330.45M |
| Account Payables | 0 | 0 | 0 | 1.63M | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.53M | 10.01M | 9.93M | 185K | 12.29M |
| Total Current Liabilities | 22.17M | 39.17M | 48.51M | 40.68M | 30.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 80K | 2.6M | 2.94M | 1.14M | 1.06M |
| Total Non-current Liabilities | 20.13M | 22.95M | 25.26M | 23.78M | 23.02M |
| Total Liabilities | 42.3M | 62.12M | 73.77M | 64.47M | 53.23M |
| Common Stock | 645K | 791K | 903K | 1.07M | 1.08M |
| Retained Earnings | (491.91M) | (713.78M) | (959.37M) | (1.22B) | (1.44B) |
| Accumulated OCI | (161K) | (357K) | 319K | 66K | (31K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 454.72M | 489.69M | 492.57M | 463.23M | 277.22M |
| Total Debt | 22.6M | 22.87M | 25.04M | 25.5M | 24.88M |
| Net Debt | (210.09M) | (117.65M) | (30.86M) | (138.14M) | (52.68M) |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.